Syndax Pharmaceuticals, Inc. (SNDX)

NASDAQ: SNDX · IEX Real-Time Price · USD
20.11
-0.59 (-2.85%)
Jun 14, 2024, 4:00 PM EDT - Market closed
-2.85%
Market Cap 1.71B
Revenue (ttm) n/a
Net Income (ttm) -240.63M
Shares Out 84.99M
EPS (ttm) -3.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 739,350
Open 20.52
Previous Close 20.70
Day's Range 19.98 - 20.58
52-Week Range 11.22 - 25.34
Beta 1.01
Analysts Strong Buy
Price Target 34.92 (+73.65%)
Earnings Date Aug 1, 2024

About SNDX

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 3, 2016
Employees 184
Stock Exchange NASDAQ
Ticker Symbol SNDX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price forecast is $34.92, which is an increase of 73.65% from the latest price.

Price Target
$34.92
(73.65% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress

- Data continue to support revumenib's potential to enhance current standard of care agents - - 96% CRc (23 of 24 pts) observed in BEAT AML trial exploring revumenib in combination with venetoclax/aza...

18 hours ago - PRNewsWire

Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC

– IDMC recommendation to advance based on favorable safety profile observed in Phase 1a portion of trial – WALTHAM, Mass. , June 6, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinic...

8 days ago - PRNewsWire

Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference

WALTHAM, Mass. , June 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced t...

9 days ago - PRNewsWire

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WALTHAM, Mass. , June 3, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced t...

11 days ago - PRNewsWire

Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors

WALTHAM, Mass. , May 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced t...

4 weeks ago - PRNewsWire

Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference

WALTHAM, Mass. , May 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced th...

5 weeks ago - PRNewsWire

Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

– NDA filing for revumenib in R/R KMT2Ar acute leukemia granted Priority Review under RTOR; PDUFA action date set for September 26, 2024 – – BLA filing for axatilimab in chronic GVHD granted Priority ...

5 weeks ago - PRNewsWire

Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024

WALTHAM, Mass. , May 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced th...

6 weeks ago - PRNewsWire

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum

WALTHAM, Mass. , April 10, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced...

2 months ago - PRNewsWire

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

– Consistent safety and efficacy profiles across adult and pediatric populations – – Majority of pediatric patients who achieved an overall response proceeded to transplant; patients receiving post-tr...

2 months ago - PRNewsWire

Under-the-radar biotech bets

Michelle Ross, StemPoint Capital CIO, joins CNBC's Halftime Report' to discuss her latest biotech pick.

Other symbols: CRNXMRUSXBI
2 months ago - CNBC Television

Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

– Topline data expected in 4Q24 could support sNDA filing in 1H25 – – Revumenib has the potential to address $2 billion mNPM1 and KMT2Ar R/R acute leukemia U.S. market opportunity – WALTHAM, Mass. , M...

2 months ago - PRNewsWire

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

– PDUFA action date set for September 26, 2024 – – NDA being reviewed under FDA's RTOR program – WALTHAM, Mass., March 26, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage ...

2 months ago - PRNewsWire

Syndax Announces Appointment of Steven Closter as Chief Commercial Officer

– Steven Closter brings more than 30 years of commercial experience in the biopharmaceutical industry to Syndax – – Company on track for two potential first- and best-in-class product launches in 2024...

3 months ago - PRNewsWire

Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

– BLA filing for axatilimab in chronic GVHD granted Priority Review; PDUFA action date set for August 28, 2024 – – NDA for revumenib in R/R KMT2Ar acute leukemia submitted under FDA's RTOR program; PD...

3 months ago - PRNewsWire

Syndax Announces Participation at Two Upcoming Investor Conferences

WALTHAM, Mass. , Feb. 26, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced ...

3 months ago - PRNewsWire

Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024

WALTHAM, Mass. , Feb. 20, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced ...

4 months ago - PRNewsWire

Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass. , Jan. 2, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced t...

5 months ago - PRNewsWire

Syndax Highlights Recent Updates and Anticipated 2024 Milestones

– BLA submitted for axatilimab in chronic graft-versus-host disease; Syndax exercised option to co-commercialize axatilimab in the U.S. with Incyte – – NDA submitted for revumenib in R/R KMT2Ar acute ...

5 months ago - PRNewsWire

Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

WALTHAM, Mass. , Dec. 19, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeli...

6 months ago - PRNewsWire

Syndax Announces Pricing of $200 Million Public Offering of Common Stock

WALTHAM, Mass. , Dec. 14, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of ...

6 months ago - PRNewsWire

Syndax Announces Proposed $150 Million Public Offering of Common Stock

WALTHAM, Mass. , Dec. 14, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of ...

6 months ago - PRNewsWire

Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

– Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); CR/CRh rate consistent across adult and pediatric patients – – 63%...

6 months ago - PRNewsWire

Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials

- Data collectively highlight revumenib's combination potential with current standard of care agents and support advancement into pivotal combination trials in the frontline setting - - 100% CRc obser...

6 months ago - PRNewsWire

Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting

WALTHAM, Mass. , Dec. 4, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced t...

6 months ago - PRNewsWire